This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.
Lutetium [177Lu] oxodotreotide/dotatate
Key Inclusion Criteria:
GEP-NET cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven, G1 or G2 (Ki-67 index =< 20%), well differentiated GEP-NET.
or PPGL cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven PPGL.
Patients from 12 to < 18 years of age at the time of enrollment.
Expression of somatostatin receptors confirmed by a somatostatin receptor imaging (SRI) modality within 3 months prior to enrollment, with tumor uptake observed in the target lesions more or equal to the normal liver uptake.
Performance status as determined by Karnofsky score >= 50 or Lansky Play-Performance Scale score >= 50.
Parent's ability to understand and the willingness to sign a written informed consent document for adolescents as determined by local regulations. Adolescents will sign assent along with parental/legal guardian consent or will co-sign consent with parent/legal guardian in accordance with local regulation, prior to participation in the study.
Key Exclusion Criteria:
Estimated creatinine clearance calculated by the Cockroft-Gault method < 70 mL/min
Hb concentration <5.0 mmol/L (<8.0 g/dL); WBC <2x109/L; platelets <75x109/L.
Total bilirubin >3 x ULN for age.
Serum albumin <3.0 g/dL unless prothrombin time is within the normal range.
Established or suspected pregnancy.
Breastfeeding female patients unless they accept to discontinue breastfeeding from the 1st dose until 3 months after the last administration of study drug.
Female patients of child-bearing potential, unless they are using highly effective methods of contraception during treatment and for 6 months after the last dose of Lutathera.
Sexually active male patients, unless they agree to remain abstinent or be willing to use effective methods of contraception.
Patients for whom in the opinion of the investigator other therapeutic options are considered more appropriate than the therapy offered in the study, based on patient and disease characteristics.
Current spontaneous urinary incontinence.
Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years.
Hypersensitivity to the study drug active substance or to any of the excipients.
Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study.
Patient with known incompatibility to CT Scans with I.V. contrast due to allergic reaction or renal insufficiency. If such a patient can be imaged with MRI, then the patient would not be excluded.
Patients who received any investigational agent within the last 30 days.
University Hospitals Leuven (UZ Leuven)
CHU de Québec - Université Laval
Centre Léon Berard
Bambin Gesu' Hospital
Prinses Maxima (UMC Utrecht)
Maria Sklodowska-Curie National Research Institute of Oncology
Hospital Universitari Vall d'Hebron
University College Hospital of London
University of Kentucky
Lexington,Contact: (504-278-0134) - [email protected] - Aman Chauhan, Dr,40536 - Kentucky,United States
Texas's Children Hospital
Houston,Contact: (832-824-4646) - [email protected] - Jennifer Foster, Dr,77030 - Texas,United States
Children's Hospital of Philadelphia
Philadelphia,Contact: (267-425-0126) - [email protected] - Theodore Laetsch, Dr,19104 - Pennsylvania,United States
Cincinnati Children's Hospital
Cincinnati,Contact: (513-636-4266) - [email protected] - Brian Weiss, Dr,45229-3039 - Ohio,United States
If the location of your choosing does not feature any contact detail, please reach out using the information below.